Skip to content
About
The Melanocortin System
Pipeline
Expand
Obesity
Cachexia
Additional Programs
Publications
News
Toggle Menu
Presentations
ENDO 2026: Dual MC3R/MC4R Activation Drives Weight Loss, Limits Rebound, and Preserves Lean Mass in Obese Nonhuman Primates
June 16, 2026
June 16, 2026
Oral abstract at ENDO 2026 in Chicago, IL
ENDO2026_Dual_MC3R_MC4R_NHPs
Download
Post navigation
Previous
Previous
Kalohexis Presents Data Highlighting Dual MC3R/MC4R Activation as a Novel Mechanism Designed to Drive Safer, Healthier and More Durable Weight Loss at ENDO 2026
Next
Continue
Kalohexis Appoints Xuan Hui, B.Med., M.S., Ph.D., as Director of Corporate Strategy
About
The Melanocortin System
Pipeline
Toggle child menu
Expand
Obesity
Cachexia
Additional Programs
Publications
News
Contact
